Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiveSpo Navax for RSV and Bacterial Pneumonia in Children
NCT05929599Active, not recruiting
- Sponsor
- National Hospital of Pediatrics
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial of LiveSpo Navax in pneumonia (2 arms), sponsored by National Hospital of Pediatrics. Primary endpoints: Percentage of patients with free respiratory symptoms, Number of days requiring oxygen therapy and 1 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
LiveSpo Navax
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT05929599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929599.